scholarly journals Engineering nanoparticles to overcome the mucus barrier for drug delivery: Design, evaluation and state-of-the-art

2021 ◽  
pp. 100110
Author(s):  
Chang Liu ◽  
Xiaohe Jiang ◽  
Yong Gan ◽  
Miaorong Yu
Keyword(s):  
Drug Delivery ◽  
State Of The Art ◽  
Design Evaluation ◽  
Mucus Barrier

Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives

2020 ◽  
Vol 10 ◽  
Author(s):  
Sapna Saini ◽  
Sanju Nanda ◽  
Anju Dhiman
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
State Of The Art ◽  
Chitosan Nanoparticles ◽  
Delivery Systems ◽  
Intrinsic Properties ◽  
Amino Groups ◽  
Suitable Candidate ◽  
Film Forming ◽  
Novel Drug

: Chitosan, a natural biodegradable polymer obtained from deacetylation of chitin, has been used as an approbative macromolecule for the development of various novel drug delivery systems. It is one of the most favorable biodegradable carriers for nanoparticulate drug delivery due to its intrinsic properties, such as biocompatibility, biodegradability, non-toxicity, availability of free reactive amino groups, and ease of chemical modification into different active derivatives. Furthermore, interesting physical properties (film-forming, gelling and thickening) make it a suitable candidate for formulations, such as films, microcapsules, beads, nanoparticles, nanofibres, nanogel and so on. Researchers have reported that chitosan nanoparticles act as a promising vehicle for herbal actives as they provide a superior alternative to traditional carriers and improve pharmaceutical efficiency. As no review of chitosan nanoparticles encapsulating herbal extracts and bioactives has been published till date, a maiden effort has been made to collate and review the use of chitosan nanoparticles for the entrapment of phytoconstituents to yield stable, efficient and safe drug delivery systems. Additionally, the paper presents a comprehensive account of the state-of the-art in fabricating herbal chitosan nanoparticles and their current pharmacological status. A list of patents on chitosan nanoparticles of herbal actives has also been included. This review is intended to serve as a didactic discourse for the formulation scientists endeavoring to develop advanced delivery systems for herbal actives.

scholarly journals The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares

2021 ◽  
Vol 13 ◽  
pp. 251584142110127
Author(s):  
Preeya K. Gupta ◽  
Nandini Venkateswaran
Keyword(s):  
Drug Delivery ◽  
Dry Eye ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Short Term ◽  
Short Term Treatment ◽  
Loteprednol Etabonate ◽  
Mucus Barrier

The tear film, which includes mucins that adhere to foreign particles, rapidly clears allergens and pathogens from the ocular surface, protecting the underlying tissues. However, the tear film’s ability to efficiently remove foreign particles during blinking can also pose challenges for topical drug delivery, as traditional eye drops (solutions and suspensions) are cleared from the ocular surface before the drug can penetrate into the conjunctival and corneal epithelium. In the past 15 years, there has been an increase in the development of nanoparticles with specialized coatings that have reduced affinity to mucins and are small enough in size to pass through the mucus barrier. These mucus-penetrating particles (MPPs) have been shown to efficiently penetrate the mucus barrier and reach the ocular surface tissues. Dry eye disease (DED) is a common inflammatory ocular surface disorder that often presents with periodic flares (exacerbations). However, currently approved immunomodulatory treatments for DED are intended for long-term use. Thus, there is a need for effective short-term treatments that can address intermittent flares of DED. Loteprednol etabonate, an ocular corticosteroid, was engineered to break down rapidly after administration to the ocular surface tissues and thereby reduce risks associated with other topical steroids. KPI-121 is an ophthalmic suspension that uses the MPP technology to deliver loteprednol etabonate more efficiently to the ocular tissues, achieving in animal models a 3.6-fold greater penetration of loteprednol etabonate to the cornea than traditional loteprednol etabonate ophthalmic suspensions. In clinical trials, short-term treatment with KPI-121 0.25% significantly reduced signs and symptoms of DED compared with its vehicle (placebo). Recently approved KPI-121 0.25%, with its novel drug delivery design and ease of use, has the potential to effectively treat periodic flares of DED experienced by many patients.

scholarly journals Drug-eluting embolic microspheres for local drug delivery – State of the art

2017 ◽  
Vol 262 ◽  
pp. 127-138 ◽  
Author(s):  
Katrin Fuchs ◽  
Rafael Duran ◽  
Alban Denys ◽  
Pierre E. Bize ◽  
Gerrit Borchard ◽  
...  
Keyword(s):  
Drug Delivery ◽  
State Of The Art ◽  
Local Drug Delivery ◽  
Drug Eluting

State-of-the-art of design, evaluation, and operation methodologies in product service systems

2016 ◽  
Vol 77 ◽  
pp. 1-14 ◽  
Author(s):  
Min Qu ◽  
Suihuai Yu ◽  
Dengkai Chen ◽  
Jianjie Chu ◽  
Baozhen Tian
Keyword(s):  
State Of The Art ◽  
Service Systems ◽  
Design Evaluation ◽  
Product Service ◽  
Product Service Systems

Nanomedicines for Ocular NSAIDs: State-of-the-Art Update of the Safety on Drug Delivery

2020 ◽  
pp. 457-524
Author(s):  
Joana R. Campos ◽  
Joana Araújo ◽  
Elisabet Gonzalez-Mira ◽  
Maria A. Egea ◽  
Elena Sanchez-Lopez ◽  
...  
Keyword(s):  
Drug Delivery ◽  
State Of The Art

Polymers in Drug Delivery-State of the Art and Future Trends

2011 ◽  
Vol 13 (3) ◽  
pp. B61-B87 ◽  
Author(s):  
Stefan Grund ◽  
Marius Bauer ◽  
Dagmar Fischer
Keyword(s):  
Drug Delivery ◽  
State Of The Art ◽  
Future Trends

State-of-the-art methods in clinical intracochlear drug delivery

2019 ◽  
Vol 27 (5) ◽  
pp. 381-386 ◽  
Author(s):  
Oliver Y. Chin ◽  
Rodney C. Diaz
Keyword(s):  
Drug Delivery ◽  
State Of The Art ◽  
Art Methods
Sign in / Sign up

Export Citation Format

Share Document